Mizusawa H, Komatsu A, Mimura Y, Maejima T. Development of male breast cancer in a patient with prostate cancer during androgen deprivation therapy.
IJU Case Rep 2022;
5:118-121. [PMID:
35252796 PMCID:
PMC8888017 DOI:
10.1002/iju5.12409]
[Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 12/10/2021] [Indexed: 11/23/2022] Open
Abstract
Introduction
Male breast cancer accounts for <1% of all breast cancer. We report a patient with prostate cancer during hormone therapy who developed breast cancer.
Case presentation
An 88‐year‐old male underwent androgen deprivation therapy for prostate cancer and developed an induration in the left breast 7 years after the start of treatment. After close examination, he was diagnosed with left breast cancer with lymph node metastasis. The prostate cancer was stable in a hormone‐sensitive state. Left mastectomy was performed and the pathological diagnosis was invasive ductal carcinoma.
Discussion
In addition to our patient, seven patients who developed breast cancer during hormone therapy for prostate cancer were examined. Five of six patients had stage II or above, and four patients had lymph node metastases. Although local breast symptoms are frequently observed as adverse effects of hormone therapy, caution is warranted regarding male breast cancer.
Collapse